Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal By Reuters
(Reuters) -Vertex Pharmaceuticals will buy Alpine Immune Sciences (NASDAQ:) for about $4.9 billion in cash, gaining access to the biotech firm's treatment for an autoimmune disease of the kidney, the companies said on Wednesday. The deal…